Related Experiment Video

Updated: Jul 4, 2026

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Generative AI-Based Drug Design: Target-Aware Molecular Generation for EGFR Type I Inhibitors with Multiplatform

Taqdees Khan1, Young Beom Kwak1,2, Hee Cheol Kim1

  • 1Department of Digital Anti-Aging Healthcare, Inje University, Gimhae-si 50834, Republic of Korea.

ACS Omega
|July 3, 2026
PubMed

Insights

This study introduces a novel computational framework using generative models to design new epidermal growth factor receptor (EGFR) inhibitors that overcome drug resistance mutations. The method successfully generated potential drug candidates targeting specific binding sites, advancing early-stage drug discovery.

Area of Science:

  • Medicinal Chemistry
  • Computational Biology
  • Drug Discovery

Background:

  • Developing selective kinase inhibitors, especially for epidermal growth factor receptor (EGFR) mutations like T790M and C797S, is crucial for oncology therapeutics.
  • Resistance mutations in EGFR present significant challenges, necessitating innovative strategies to identify inhibitors that circumvent these resistance mechanisms.

Purpose of the Study:

  • To propose and validate a target-conditioned generative framework for designing novel EGFR inhibitors that overcome resistance mutations.
  • To incorporate protein structural information, specifically the ATP-binding pocket, into the generative process for enhanced inhibitor design.

Main Methods:

  • A structure-aware conditioning approach using a Long Short-Term Memory network was employed, guided by 20 key residues from the EGFR crystal structure (PDB 1M17).
  • Training utilized 6,038 Type I EGFR inhibitors from the ChEMBL database, filtered for drug-like properties.
  • Generated molecules were evaluated for chemical validity, novelty, binding affinity (AutoDock Vina), and target-site specificity (CB-Dock2).

Main Results:

  • The framework achieved 82.6% chemical validity and 79.5% novelty among 1000 generated sequences.
  • Five prioritized candidates showed superior predicted binding scores (-7.7 to -8.4 kcal/mol) compared to erlotinib (-7.57 kcal/mol) and exhibited zero Lipinski violations.
  • Cross-validation confirmed consistent targeting of the ATP-binding pocket, demonstrating target-site specificity and ATP-competitive binding modes.

Conclusions:

  • The target-conditioning mechanism significantly improved the generation of viable drug candidates compared to unconditional methods.
  • This study provides a proof-of-concept for using structure-guided generative models in rational kinase inhibitor design for early-stage drug discovery.
  • The developed computational framework offers a promising approach for identifying novel inhibitors against challenging drug targets like mutated EGFR.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...